Pharma BD Deal Intelligence
BMS never acquired Exelixis — it was a 2008 licensing deal for cabozantinib/XL281 that BMS fully unwound by 2011, handing back the asset that became Exelixis's own blockbuster Cabometyx
Full analysis, sources & comparables →BMS made a nonrefundable $195M upfront payment for worldwide development and commercialization rights to XL184 and XL281, with co-development of XL184 in the…
Cabozantinib received FDA approval for progressive metastatic medullary thyroid cancer based on the EXAM Phase 3 trial showing median PFS of 11.2 months vs…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
$195M upfront + $45M 2009 + up to $150M sales milestones + double-digit ex-US royalties; XL184 (cabozantinib) MET/VEGFR/RET, XL281 RAF kinase oncology
BMS never acquired Exelixis — it was a 2008 licensing deal for cabozantinib/XL281 that BMS fully unwound by 2011, handing back the asset that became Exelixis's own blockbuster Cabometyx
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / Exelixis Inc. (this deal) | 2008 | $240M | 10 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |